Carisma Therapeutics, Inc. - Common Stock
Performance History
| Key Stats | |
|---|---|
| Open | $2.40 |
| Prev. Close | $2.36 |
| EPS | -1.21 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 10, 2023 |
| Dividend Yield % | 66.19% |
| Market Cap | $100.89M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 2.31 | 2.53 |
| 52 Week Range | 2.18 | 13.00 |
| Ratios | |
|---|---|
| P/B Ratio | 0.00 |
| Revenue | $10.63M |
| Operating M. % | -588.90% |
| Earnings | -$53.63M |
| Earnings Growth % | - |
| EBITDA Margin % | -656.26% |
| ROE % | -239.28% |
| EPS | -1.21 |
Score Breakdown
All Score (51 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| CARM | Market | |
|---|---|---|
| Value | 65 | 42 |
| Quality | 60 | 46 |
| Ownership | 38 | 39 |
| Growth | 19 | 44 |
| Dividends | 33 | 32 |
All Score (51 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Carisma Therapeutics, Inc. - Common Stock (CARM)
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Steven Kelly
- Headquarters
- Philadelphia
- Employees
- 0
Keep an eye on Carisma Therapeutics, Inc. - Common Stock
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.